Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate CTX-712 in Advanced, Relapsed or Refractory Malignant Cancer Patients

Next Previous
Trial Profile

A Study to Evaluate CTX-712 in Advanced, Relapsed or Refractory Malignant Cancer Patients

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CTX 712 (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Chordia Therapeutics

Most Recent Events

  • 10 Apr 2024 Results (n=46) presented at the 115th Annual Meeting of the American Association for Cancer Research
  • 13 Dec 2022 Results (n=6; As of April 28, 2022) assessing the dose escalation cohort of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes, including preliminary efficacy results of CTX-712, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 07 Jun 2022 Results (As of Dec. 31, 2021, n=30 ) presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top